Skip to content
2000
image of A Relationship between Inflammatory Bowel Diseases and Urinary Lithiasis

Abstract

Objective

Ulcerative colitis (UC) and Crohn's disease (CD) are two forms of inflammatory bowel disease (IBD) and may be associated with the formation of urinary stones. Urinary lithiasis is a common condition that affects both men and women, and its prevalence is increasing due to dietary and environmental factors. Understanding the association between IBD and urolithiasis is important for the comprehensive treatment of patients. This review aims to evaluate the relationship between IBD and the formation of urinary calculi.

Methodology

PubMed/Medline database was used using the keywords simultaneously: (Inflammatory Bowel Disease) or (Crohn’s Disease) or (Ulcerative Colitis) and (Urolithiasis). After the preliminary search, 61 of 111 studies on the subject were examined. Other studies were included by the authors.

Results

Urinary lithiasis is more prevalent in patients with Inflammatory Bowel Disease. The latter can be described as a risk factor for the former.

Conclusion

Patients with IBD are at increased risk of developing urolithiasis. Despite the limitations of this study, these patients may benefit from early screening, as well as strict control of disease activity, diet, medication and behaviors.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cset/10.2174/0122102981375859250512064438
2025-05-27
2025-09-04

  • From This Site

    /content/journals/cset/10.2174/0122102981375859250512064438
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Ganji-Arjenaki M. Nasri H. Rafieian-Kopaei M. Nephrolithiasis as a common urinary system manifestation of inflammatory bowel diseases; A clinical review and meta-analysis. J. Nephropathol. 2017 6 3 264 269 10.15171/jnp.2017.42 28975110
    [Google Scholar]
  2. Levine J.S. Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol. Hepatol. 2011 7 4 235 241 21857821
    [Google Scholar]
  3. Oikonomou K. Kapsoritakis A. Eleftheriadis T. Stefanidis I. Potamianos S. Renal manifestations and complications of inflammatory bowel disease. Inflamm. Bowel Dis. 2011 17 4 1034 1045 10.1002/ibd.21468 20842645
    [Google Scholar]
  4. van Hoeve K. Hoffman I. Renal manifestations in inflammatory bowel disease: A systematic review. J. Gastroenterol. 2022 57 9 619 629 10.1007/s00535‑022‑01903‑6 35834005
    [Google Scholar]
  5. Harbord M. Annese V. Vavricka S.R. Allez M. Barreiro-de Acosta M. Boberg K.M. Burisch J. De Vos M. De Vries A.M. Dick A.D. Juillerat P. Karlsen T.H. Koutroubakis I. Lakatos P.L. Orchard T. Papay P. Raine T. Reinshagen M. Thaci D. Tilg H. Carbonnel F. The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J. Crohn’s Colitis 2016 10 3 239 254 10.1093/ecco‑jcc/jjv213 26614685
    [Google Scholar]
  6. Hueppelshaeuser R. von Unruh G.E. Habbig S. Beck B.B. Buderus S. Hesse A. Hoppe B. Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn’s disease. Pediatr. Nephrol. 2012 27 7 1103 1109 10.1007/s00467‑012‑2126‑8 22366809
    [Google Scholar]
  7. Gasche C. Complications of inflammatory bowel disease. Hepatogastroenterology 2000 47 31 49 56 10690585
    [Google Scholar]
  8. Manganiotis AN Banner MP Malkowicz SB Urologic complications of Crohn's disease. Surg. Clin. North Am. 2001 81 1 197 215 10.1016/S0039‑6109(05)70281‑4
    [Google Scholar]
  9. Adler G Reinshagen M Extraintestinale manifestationen. Z. Gastroenterol. 2003 41 1 54 61 10.1055/s‑2003‑36670
    [Google Scholar]
  10. Oefelein M.G. Urologic manifestations of nonurologic diseases. Urol. Clin. North Am. 2003 30 1 63 72 10.1016/S0094‑0143(02)00110‑6 12580558
    [Google Scholar]
  11. Yumura Y Oota J Fujikawa A Yokomizo Y Moriyama M. The relationship between inflammatory bowel disease (IBD) and complications of urinary and male genital tracts. Hinyokika Kiyo 2009 55 11 677 683
    [Google Scholar]
  12. Awedew A.F. Han H. Berice B.N. Dodge M. Schneider R.D. Abbasi-Kangevari M. Al-Aly Z. Almidani O. Alvand S. Arabloo J. Aravkin A.Y. Ayana T.M. Bhardwaj N. Bhardwaj P. Bhaskar S. Bikbov B. Caetano dos Santos F.L. Charan J. Cruz-Martins N. Dadras O. Dai X. Digesa L.E. Elhadi M. Elmonem M.A. Esezobor C.I. Fatehizadeh A. Gebremeskel T.G. Getachew M.E. Ghamari S-H. Hay S.I. Ilic I.M. Ilic M.D. Jayarajah U. Jazayeri S.B. Kim M.S. Lee S-W. Lee S.W.H. Lim S.S. Mahmoud M.A. Malik A.A. Mentis A-F.A. Mestrovic T. Michalek I.M. Mihrtie G.N. Mirrakhimov E.M. Mokdad A.H. Moni M.A. Moradi M. Murray C.J.L. Ortiz A. Pawar S. Perico N. Rashidi M-M. Rawassizadeh R. Remuzzi G. Schumacher A.E. Singh J.A. Skryabin V.Y. Skryabina A.A. Tan K-K. Tolani M.A. Valadan Tahbaz S. Valizadeh R. Vo B. Wolde A.A. Yahyazadeh Jabbari S.H. Yazdanpanah F. Yiğit A. Yiğit V. Zahir M. Zastrozhin M. Zhang Z-J. Zumla A. Misganaw A. Dirac M.A. The global, regional, and national burden of urolithiasis in 204 countries and territories, 2000–2021: A systematic analysis for the global burden of disease study 2021. EClinicalMedicine 2024 78 102924 10.1016/j.eclinm.2024.102924
    [Google Scholar]
  13. Wang R. Li Z. Liu S. Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: A systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open 2023 13 3 e065186 10.1136/bmjopen‑2022‑065186 36977543
    [Google Scholar]
  14. Ben-Ami H. Ginesin Y. Behar D.M. Fisher D. Edoute Y. Lavy A. Diagnosis and treatment of urinary tract complications in Crohn’s disease: An experience over 15 years. Can. J. Gastroenterol. 2002 16 4 225 229 10.1155/2002/204614 11981574
    [Google Scholar]
  15. McConnell N. Campbell S. Gillanders I. Rolton H. Danesh B. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int. 2002 89 9 835 841 10.1046/j.1464‑410X.2002.02739.x 12010224
    [Google Scholar]
  16. Stark C.M. Gorman G.H. Nylund C.M. Association of inflammatory bowel disease and urolithiasis in hospitalized pediatric patients. Inflamm. Bowel Dis. 2017 23 10 1777 1782 10.1097/MIB.0000000000001188 28696957
    [Google Scholar]
  17. Fagagnini S. Heinrich H. Rossel J.B. Biedermann L. Frei P. Zeitz J. Spalinger M. Battegay E. Zimmerli L. Vavricka S.R. Rogler G. Scharl M. Misselwitz B. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS One 2017 12 10 e0185193 10.1371/journal.pone.0185193 29023532
    [Google Scholar]
  18. Scales C.D. Smith A.C. Hanley J.M. Saigal C.S. Prevalence of kidney stones in the United States. Eur. Urol. 2012 62 1 160 165 10.1016/j.eururo.2012.03.052 22498635
    [Google Scholar]
  19. Stamatelou K.K. Francis M.E. Jones C.A. Nyberg L.M. Curhan G.C. Time trends in reported prevalence of kidney stones in the United States: 1976–199411. See Editorial by Goldfarb, p. 1951. Kidney Int. 2003 63 5 1817 1823 10.1046/j.1523‑1755.2003.00917.x 12675858
    [Google Scholar]
  20. Pearle M.S. Calhoun E.A. Curhan G.C. Urologic diseases in America project: Urolithiasis. J. Urol. 2005 173 3 848 857 10.1097/01.ju.0000152082.14384.d7 15711292
    [Google Scholar]
  21. Corica D. Romano C. Renal involvement in inflammatory bowel diseases. J. Crohn’s Colitis 2016 10 2 226 235 10.1093/ecco‑jcc/jjv138 26223844
    [Google Scholar]
  22. Parks J.H. Worcester E.M. O’Connor R.C. Coe F.L. Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int. 2003 63 1 255 265 10.1046/j.1523‑1755.2003.00725.x 12472791
    [Google Scholar]
  23. Kumar R. Ghoshal U.C. Singh G. Mittal R.D. Infrequency of colonization with Oxalobacter formigenes in inflammatory bowel disease: Possible role in renal stone formation. J. Gastroenterol. Hepatol. 2004 19 12 1403 1409 10.1111/j.1440‑1746.2004.03510.x 15610315
    [Google Scholar]
  24. Kim M.J. Woo S. Kim E.R. Hong S.N. Chang D.K. Rhee P.L. Kim J.J. Rhee J.C. Kim Y.H. Incidence and risk factors for urolithiasis in patients with crohn’s disease. Urol. Int. 2015 95 3 314 319 10.1159/000375536 25895526
    [Google Scholar]
  25. Dimke H. Winther-Jensen M. Allin K.H. Lund L. Jess T. Risk of urolithiasis in patients with inflammatory bowel disease: A nationwide danish cohort study 1977–2018. Clin. Gastroenterol. Hepatol. 2021 19 12 2532 2540.e2 10.1016/j.cgh.2020.09.049 33007511
    [Google Scholar]
  26. Mak W.Y. Zhao M. Ng S.C. Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J. Gastroenterol. Hepatol. 2020 35 3 380 389 10.1111/jgh.14872 31596960
    [Google Scholar]
  27. Cury D. Moss A. Schor N. Nephrolithiasis in patients with inflammatory bowel disease in the community. Int. J. Nephrol. Renovasc. Dis. 2013 6 139 142 10.2147/IJNRD.S45466 23935383
    [Google Scholar]
  28. Viana M.L. Pontes R.M. Garcia W.E. Fávero M.E. Prete D.C. Matsuo T. Crohn's disease and kidney stones: much more than coincidence? Arq. Gastroenterol. 2007 44 3 210 214 10.1590/s0004‑28032007000300006
    [Google Scholar]
  29. Boussorra H. Sallami S. Said Y. Chebil M. Najjar T. Evaluation of urolithiasis in Crohn’s disease in Tunisian patients. Tunis. Med. 2013 91 7 440 443 24008874
    [Google Scholar]
  30. Dincer M.T. Dincer Z.T. Bakkaloglu O.K. Yalin S.F. Trabulus S. Celik A.F. Seyahi N. Altiparmak M.R. Renal manifestations in inflammatory bowel disease: A cohort study during the biologic era. Med. Sci. Monit. 2022 28 e936497 10.12659/MSM.936497 35791280
    [Google Scholar]
  31. Kumar S. Pollok R. Goldsmith D. Renal and urological disorders associated with inflammatory bowel disease. Inflamm. Bowel Dis. 2022 izac140 10.1093/ibd/izac140 35942657
    [Google Scholar]
  32. Trinchieri A. Lizzano R. Castelnuovo C. Zanetti G. Pisani E. Urinary patterns of patients with renal stones associated with chronic inflammatory bowel disease. Arch. Ital. Urol. Androl. 2002 74 2 61 64 12161938
    [Google Scholar]
  33. Torio M. Ishimura M. Ohga S. Doi T. Utsunomiya R. Ohkubo K. Suga N. Tatsugami K. Matsumoto T. Takada H. Hara T. Nephrolithiasis as an extra-intestinal presentation of pediatric inflammatory bowel disease unclassified. J. Crohn’s Colitis 2010 4 6 674 678 10.1016/j.crohns.2010.05.012 21122580
    [Google Scholar]
  34. Jung D. Alshaikh A. Ratakonda S. Bashir M. Amin R. Jeon S. Stevens J. Sharma S. Ahmed W. Musch M. Hassan H. Adenosinergic signaling inhibits oxalate transport by human intestinal Caco2-BBE cells through the A 2B adenosine receptor. Am. J. Physiol. Cell Physiol. 2018 315 5 C687 C698 10.1152/ajpcell.00024.2017 30020825
    [Google Scholar]
  35. Torricelli F.C. Reichard C. Monga M. Urolithiasis in complicated inflammatory bowel disease: A comprehensive analysis of urine profile and stone composition. Int. Urol. Nephrol. 2021 53 2 205 209 10.1007/s11255‑020‑02649‑x 32915375
    [Google Scholar]
  36. Gkentzis A. Kimuli M. Cartledge J. Traxer O. Biyani C.S. Urolithiasis in inflammatory bowel disease and bariatric surgery. World J. Nephrol. 2016 5 6 538 546 10.5527/wjn.v5.i6.538 27872836
    [Google Scholar]
  37. Assimos D.G. Re: Urolithiasis in inflammatory bowel disease and bariatric surgery. J. Urol. 2017 198 3 478 479 10.1016/j.juro.2017.06.026 28817906
    [Google Scholar]
  38. Miyajima S. Ishii T. Watanabe M. Ueki T. Tanaka M. Risk factors for urolithiasis in patients with Crohn’s disease. Int. J. Urol. 2021 28 2 220 224 10.1111/iju.14442 33191551
    [Google Scholar]
  39. Arora Z. Mukewar S. Lopez R. Camino D. Shen B. Hall P. Etiopathogenesis of nephrolithiasis in ulcerative colitis patients with the ileal pouch anal anastomosis. Inflamm. Bowel Dis. 2017 23 5 840 846 10.1097/MIB.0000000000001070 28301430
    [Google Scholar]
  40. Shi YJ Yu S Tian BW Dai YM Xu H Tan B Li Y Risk factors and characteristics of gut microbiota and metabolites in inflammatory bowel diseases patients with urolithiasis. Zhonghua Yi Xue Za Zhi 2022 102 44 3525 3531 10.3760/cma.j.cn112137‑20220519‑01111
    [Google Scholar]
  41. de la Vega L.P. Lieske J.C. Milliner D. Gonyea J. Kelly D.G. Urinary oxalate excretion increases in home parenteral nutrition patients on a higher intravenous ascorbic acid dose. JPEN J. Parenter. Enteral Nutr. 2004 28 6 435 438 10.1177/0148607104028006435 15568291
    [Google Scholar]
  42. Durando M. Tiu H. Kim J.S. Sulfasalazine-induced crystalluria causing severe acute kidney injury. Am. J. Kidney Dis. 2017 70 6 869 873 10.1053/j.ajkd.2017.05.013 28669550
    [Google Scholar]
  43. Simsek M. de Boer N.K.H. Mesalazine and nephrolithiasis: Leave no stone unturned. Am. J. Gastroenterol. 2019 114 8 1359 1360 10.14309/ajg.0000000000000311 31261253
    [Google Scholar]
  44. Yamamoto Y Kurokawa Y Oka N Takahasi M Fukumori T Shirane Y Kanayama HO Kagawa S A pediatric case of ammonium acid urate lithiasis with ulcerative colitis. Nihon Hinyokika Gakkai Zasshi 2002 93 5 652 655 10.5980/jpnjurol1989.93.652
    [Google Scholar]
  45. Joy H.M. Fairhurst J.J. Beattie M.R. Renal calculus at presentation in a child with Crohn’s disease. Pediatr. Radiol. 2003 33 4 250 252 10.1007/s00247‑002‑0819‑z 12709754
    [Google Scholar]
  46. Russinko P.J. Agarwal S. Choi M.J. Kelty P.J. Obstructive nephropathy secondary to sulfasalazine calculi. Urology 2003 62 4 748 10.1016/S0090‑4295(03)00666‑6 14550462
    [Google Scholar]
  47. Fujii T Shiba M Takatera H. A case of ammonium urate urolithiasis with Crohn's disease. Hinyokika Kiyo 2003 49 10 615 617
    [Google Scholar]
  48. Hasan M.N. Tiselius H.G. Mesalamine: A rare constituent of urinary tract concretions. Urolithiasis 2013 41 3 271 272 10.1007/s00240‑013‑0553‑z 23546224
    [Google Scholar]
  49. Corbery B. Lebdai S. Borojeni S. Bigot P. Azzouzi A.R. Culty T. Mesalazine: A novel etiology for drug-induced urinary calculi. Urol. J. 2018 15 3 132 133 10.22037/uj.v0i0.3902 29277882
    [Google Scholar]
  50. Ogawa K Sakaguchi K Oka S Nagamoto S Kurosawa K Urakami S Okaneya T. Drug-induced bilateral nephrolithiasis in an ulcerative colitis patient: A case report. J. Jpn. Soc. Chem. Res. 2019 110 1 41 46 10.5980/jpnjurol.110.41
    [Google Scholar]
  51. Vílchez A Orts JA Frédérique Scheirs S Benavent G Mesalazine renal lithiasis. Arch. Esp. Urol. 2020 73 6 561 564
    [Google Scholar]
  52. Pathan S.A. Mitra B. Straney L.D. Afzal M.S. Anjum S. Shukla D. Morley K. Hilli S.A.A. Rumaihi K.A. Thomas S.H. Cameron P.A. Delivering safe and effective analgesia for management of renal colic in the emergency department: A double-blind, multigroup, randomised controlled trial. Lancet 2016 387 10032 1999 2007 10.1016/S0140‑6736(16)00652‑8 26993881
    [Google Scholar]
  53. Pathan S.A. Mitra B. Cameron P.A. A systematic review and meta-analysis comparing the efficacy of nonsteroidal anti-inflammatory drugs, opioids, and paracetamol in the treatment of acute renal colic. Eur. Urol. 2018 73 4 583 595 10.1016/j.eururo.2017.11.001 29174580
    [Google Scholar]
  54. Safaie A. Tavoli M. Babaniamansour S. Aliniagerdroudbari E. Mousavi A. Sotoodehnia M. Bahreini M. Intravenous morphine plus ibuprofen or ketorolac versus intravenous morphine alone in reducing renal colic pain intensity in emergency department. Turk. J. Emerg. Med. 2022 22 1 8 14 10.4103/2452‑2473.336108 35284698
    [Google Scholar]
  55. Forouzanfar M.M. Mohammadi K. Hashemi B. Safari S. Comparison of intravenous ibuprofen with intravenous ketorolac in renal colic pain management; A clinical trial. Anesth. Pain Med. 2019 In Press e86963 10.5812/aapm.86963 30881914
    [Google Scholar]
  56. Schmidt M. Sørensen H.T. Pedersen L. Diclofenac use and cardiovascular risks: Series of nationwide cohort studies. BMJ 2018 362 k3426 10.1136/bmj.k3426 30181258
    [Google Scholar]
  57. Bhala N. Emberson J. Merhi A. Abramson S. Arber N. Baron J.A. Bombardier C. Cannon C. Farkouh M.E. FitzGerald G.A. Goss P. Halls H. Hawk E. Hawkey C. Hennekens C. Hochberg M. Holland L.E. Kearney P.M. Laine L. Lanas A. Lance P. Laupacis A. Oates J. Patrono C. Schnitzer T.J. Solomon S. Tugwell P. Wilson K. Wittes J. Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet 2013 382 9894 769 779 10.1016/S0140‑6736(13)60900‑9 23726390
    [Google Scholar]
  58. Guercio S. Ambu A. Mangione F. Mari M. Vacca F. Bellina M. Randomized prospective trial comparing immediate versus delayed ureteroscopy for patients with ureteral calculi and normal renal function who present to the emergency department. J. Endourol. 2011 25 7 1137 1141 10.1089/end.2010.0554 21682597
    [Google Scholar]
  59. Yallappa S. Amer T. Jones P. Greco F. Tailly T. Somani B.K. Umez-Eronini N. Aboumarzouk O.M. Natural history of conservatively managed ureteral stones: Analysis of 6600 patients. J. Endourol. 2018 32 5 371 379 10.1089/end.2017.0848 29482379
    [Google Scholar]
  60. Skolarikos A. Laguna M.P. Alivizatos G. Kural A.R. de la Rosette J.J.M.C.H. The role for active monitoring in urinary stones: A systematic review. J. Endourol. 2010 24 6 923 930 10.1089/end.2009.0670 20482232
    [Google Scholar]
  61. Shah T.T. Gao C. Peters M. Manning T. Cashman S. Nambiar A. Cumberbatch M. Lamb B. Peacock A. Van Son M.J. van Rossum P.S.N. Pickard R. Erotocritou P. Smith D. Kasivisvanathan V. Factors associated with spontaneous stone passage in a contemporary cohort of patients presenting with acute ureteric colic: Results from the Multi‐centre cohort study evaluating the role of Inflammatory Markers In patients presenting with acute ureteric Colic (MIMIC) study. BJU Int. 2019 124 3 504 513 10.1111/bju.14777 31001912
    [Google Scholar]
  62. Dellabella M. Milanese G. Muzzonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. J. Urol. 2005 174 1 167 172 10.1097/01.ju.0000161600.54732.86 15947613
    [Google Scholar]
  63. Borghi L. Meschi T. Amato F. Novarini A. Giannini A. Quarantelli C. Mineo F. Nifedipine and methylprednisolone in facilitating ureteral stone passage: A randomized, double-blind, placebo-controlled study. J. Urol. 1994 152 4 1095 1098 10.1016/S0022‑5347(17)32511‑9 8072071
    [Google Scholar]
  64. Porpiglia F. Destefanis P. Fiori C. Fontana D. Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. Urology 2000 56 4 579 582 10.1016/S0090‑4295(00)00732‑9 11018608
    [Google Scholar]
  65. Dellabella M. Milanese G. Muzzonigro G. Medical-expulsive therapy for distal ureterolithiasis: Randomized prospective study on role of corticosteroids used in combination with tamsulosin—simplified treatment regimen and health-related quality of life. Urology 2005 66 4 712 715 10.1016/j.urology.2005.04.055 16230122
    [Google Scholar]
  66. Pickard R. Starr K. MacLennan G. Lam T. Thomas R. Burr J. McPherson G. McDonald A. Anson K. N’Dow J. Burgess N. Clark T. Kilonzo M. Gillies K. Shearer K. Boachie C. Cameron S. Norrie J. McClinton S. Medical expulsive therapy in adults with ureteric colic: A multicentre, randomised, placebo-controlled trial. Lancet 2015 386 9991 341 349 10.1016/S0140‑6736(15)60933‑3 25998582
    [Google Scholar]
  67. Furyk J.S. Chu K. Banks C. Greenslade J. Keijzers G. Thom O. Torpie T. Dux C. Narula R. Distal ureteric stones and tamsulosin: A double-blind, placebo-controlled, randomized, multicenter trial. Ann. Emerg. Med. 2016 67 1 86 95.e2 10.1016/j.annemergmed.2015.06.001 26194935
    [Google Scholar]
  68. Sur R.L. Shore N. L’Esperance J. Knudsen B. Gupta M. Olsen S. Shah O. Silodosin to facilitate passage of ureteral stones: A multi-institutional, randomized, double-blinded, placebo-controlled trial. Eur. Urol. 2015 67 5 959 964 10.1016/j.eururo.2014.10.049 25465978
    [Google Scholar]
  69. Türk C. Knoll T. Seitz C. Skolarikos A. Chapple C. McClinton S. Medical expulsive therapy for ureterolithiasis: The EAU recommendations in 2016. Eur. Urol. 2017 71 4 504 507 10.1016/j.eururo.2016.07.024 27506951
    [Google Scholar]
  70. Ye Z. Zeng G. Yang H. Tang K. Zhang X. Li H. Li W. Wu Z. Chen L. Chen X. Liu X. Deng Y. Pan T. Xing J. Wang S. Cheng Y. Gu X. Gao W. Yang J. Zhang Y. Mi Q. Qi L. Li J. Hu W. Liang P. Sun Z. Xu C. Long Y. Liao Y. Liu S. Liu G. Xu X. He W. Chen Z. Xu H. Efficacy and safety of tamsulosin in medical expulsive therapy for distal ureteral stones with renal colic: A multicenter, randomized, double-blind, placebo-controlled trial. Eur. Urol. 2018 73 3 385 391 10.1016/j.eururo.2017.10.033 29137830
    [Google Scholar]
  71. Ong A. Brown G. Tokas T. Hameed B.M.Z. Philip J. Somani B.K. Selection and outcomes for dissolution therapy in uric acid stones: A systematic review of literature. Curr. Urol. Rep. 2023 24 8 355 363 10.1007/s11934‑023‑01164‑7 37079196
    [Google Scholar]
  72. El-Gamal O. El-Bendary M. Ragab M. Rasheed M. Role of combined use of potassium citrate and tamsulosin in the management of uric acid distal ureteral calculi. Urol. Res. 2012 40 3 219 224 10.1007/s00240‑011‑0406‑6 21858663
    [Google Scholar]
  73. Skolarikos A. Mitsogiannis H. Deliveliotis C. Indications, prediction of success and methods to improve outcome of shock wave lithotripsy of renal and upper ureteral calculi. Arch. Ital. Urol. Androl. 2010 82 1 56 63 20593724
    [Google Scholar]
  74. Preminger G.M. Tiselius H.G. Assimos D.G. Alken P. Buck A.C. Gallucci M. Knoll T. Lingeman J.E. Nakada S.Y. Pearle M.S. Sarica K. Türk C. Wolf J.S. European association of urology. 2007 guideline for the management of ureteral calculi. Eur. Urol. 2007 52 6 1610 1631 10.1016/j.eururo.2007.09.039 18074433
    [Google Scholar]
  75. Lai S. Jiao B. Diao T. Seery S. Hu M. Wang M. Hou H. Wang J. Zhang G. Liu M. Optimal management of large proximal ureteral stones (>10 mm): A systematic review and meta-analysis of 12 randomized controlled trials. Int. J. Surg. 2020 80 205 217 10.1016/j.ijsu.2020.06.025 32622059
    [Google Scholar]
  76. Peng C.X. Lou Y.K. Xu L. Wu G.H. Zhou X.L. Wang K.E. Ye C.H. Efficacy of emergency extracorporeal shock wave lithotripsy in the treatment of ureteral stones: A meta-analysis. BMC Urol. 2023 23 1 56 10.1186/s12894‑023‑01226‑5 37016405
    [Google Scholar]
  77. Alsawi M. Nalagatla S. Ahmad N. Chandiramani A.S. Mokool L. Nalagatla S.K. Somani B. Aboumarzouk O.M. Amer T. Primary versus delayed ureteroscopy for ureteric stones: A systematic review and meta-analysis. J. Clin. Urol. 2024 17 5 489 503 10.1177/20514158221088687
    [Google Scholar]
  78. Tzelves L. Geraghty R. Mourmouris P. Chatzikrachtis N. Karavitakis M. Somani B. Skolarikos A. Shockwave lithotripsy complications according to modified clavien-dindo grading system. A systematic review and meta-regression analysis in a sample of 115 randomized controlled trials. Eur. Urol. Focus 2022 8 5 1452 1460 10.1016/j.euf.2021.11.002 34848163
    [Google Scholar]
  79. Wang W. Peng L. Di X. Gao X. Wei X. Does previous unsuccessful shockwave lithotripsy influence the outcomes of ureteroscopy?—a systematic review and meta-analysis. Transl. Androl. Urol. 2021 10 5 2122 2132 10.21037/tau‑21‑39 34159093
    [Google Scholar]
  80. Drake T. Grivas N. Dabestani S. Knoll T. Lam T. Maclennan S. Petrik A. Skolarikos A. Straub M. Tuerk C. Yuan C.Y. Sarica K. What are the benefits and harms of ureteroscopy compared with shock-wave lithotripsy in the treatment of upper ureteral stones? A systematic review. Eur. Urol. 2017 72 5 772 786 10.1016/j.eururo.2017.04.016 28456350
    [Google Scholar]
  81. Dasgupta R. Cameron S. Aucott L. MacLennan G. Thomas R.E. Kilonzo M.M. Lam T.B.L. N’Dow J. Norrie J. Anson K. Burgess N. Clark C.T. Keeley F.X. MacLennan S.J. Starr K. McClinton S. Shockwave lithotripsy versus ureteroscopic treatment as therapeutic interventions for stones of the ureter (TISU): A multicentre randomised controlled non-inferiority trial. Eur. Urol. 2021 80 1 46 54 10.1016/j.eururo.2021.02.044 33810921
    [Google Scholar]
  82. Güler Y. Non-contrast computed tomography-based factors in predicting ESWL success: A systematic review and meta-analysis. Prog. Urol. 2023 33 1 27 47 10.1016/j.purol.2022.09.015 36202729
    [Google Scholar]
  83. López M. Hoppe B. History, epidemiology and regional diversities of urolithiasis. Pediatr. Nephrol. 2010 25 1 49 59 10.1007/s00467‑008‑0960‑5 21476230
    [Google Scholar]
  84. Reynolds T.M. ACP best practice no 181: Chemical pathology clinical investigation and management of nephrolithiasis. J. Clin. Pathol. 2005 58 2 134 140 10.1136/jcp.2004.019588 15677531
    [Google Scholar]
  85. Cirillo M Iudici M Marcarelli F Laudato M Zincone F Nephrolithiasis in patients with intestinal diseases. G. Ital. Nefrol. 2008 25 1 42 48
    [Google Scholar]
  86. Fink H.A. Akornor J.W. Garimella P.S. MacDonald R. Cutting A. Rutks I.R. Monga M. Wilt T.J. Diet, fluid, or supplements for secondary prevention of nephrolithiasis: A systematic review and meta-analysis of randomized trials. Eur. Urol. 2009 56 1 72 80 10.1016/j.eururo.2009.03.031 19321253
    [Google Scholar]
  87. Rodgers A.L. Allie-Hamdulay S. Jackson G.E. Sutton R.A.L. Enteric hyperoxaluria secondary to small bowel resection: Use of computer simulation to characterize urinary risk factors for stone formation and assess potential treatment protocols. J. Endourol. 2014 28 8 985 994 10.1089/end.2014.0077 24773381
    [Google Scholar]
  88. Hoppe B. Leumann E. von Unruh G. Laube N. Hesse A. Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria. Front. Biosci. 2003 8 5 1135 10.2741/1135 12957811
    [Google Scholar]
  89. İbis M.A. Oktar A. Gokce M.I. Dietary advice for patients with bowel-related conditions and malabsorption. World J. Urol. 2023 41 5 1235 1242 10.1007/s00345‑023‑04281‑7 36648528
    [Google Scholar]
  90. Alon U.S. Medical treatment of pediatric urolithiasis. Pediatr. Nephrol. 2009 24 11 2129 2135 10.1007/s00467‑007‑0740‑7 18273648
    [Google Scholar]
  91. Mukewar S. Hall P. Lashner B.A. Lopez R. Kiran R.P. Shen B. Risk factors for nephrolithiasis in patients with ileal pouches. J. Crohn’s Colitis 2013 7 1 70 78 10.1016/j.crohns.2012.05.006 22728147
    [Google Scholar]
  92. Lieske J.C. Goldfarb D.S. De Simone C. Regnier C. Use of a probioitic to decrease enteric hyperoxaluria. Kidney Int. 2005 68 3 1244 1249 10.1111/j.1523‑1755.2005.00520.x 16105057
    [Google Scholar]
  93. Premakumar Y. Gadiyar N. Hameed B.M.Z. Veneziano D. Somani B.K. Association of kidney stone disease (KSD) with primary gastrointestinal surgery: A systematic review over last 2 decades. Curr. Urol. Rep. 2021 22 6 34 10.1007/s11934‑021‑01046‑w 34027628
    [Google Scholar]
  94. Ishii G. Nakajima K. Tanaka N. Hara H. Kato M. Ishii N. Clinical evaluation of urolithiasis in Crohn’s disease. Int. J. Urol. 2009 16 5 477 480 10.1111/j.1442‑2042.2009.02285.x 19341366
    [Google Scholar]
  95. Huang V. Mishra R. Thanabalan R. Nguyen G.C. Patient awareness of extraintestinal manifestations of inflammatory bowel disease. J. Crohn’s Colitis 2013 7 8 e318 e324 10.1016/j.crohns.2012.11.008 23265763
    [Google Scholar]
  96. Cullen G. Donnellan F. Long S. Forry M. Murray F.E. Perceptions of medication safety among patients with inflammatory bowel disease. Scand. J. Gastroenterol. 2010 45 9 1076 1083 10.3109/00365521.2010.490595 20459367
    [Google Scholar]
  97. Jones S.C. Gallacher B. Lobo A.J. Axon A.T.R. A patient knowledge questionnaire in inflammatory bowel disease. J. Clin. Gastroenterol. 1993 17 1 21 24 10.1097/00004836‑199307000‑00007 8409293
    [Google Scholar]
  98. Eaden J.A. Abrams K. Mayberry J.F. The Crohn’s and colitis knowledge score: A test for measuring patient knowledge in inflammatory bowel disease. Am. J. Gastroenterol. 1999 94 12 3560 3566 10.1111/j.1572‑0241.1999.01536.x 10606319
    [Google Scholar]
  99. Subasinghe D. Wijekoon N.S. Nawarathne N.M. Samarasekera D.N. Disease-related knowledge in inflammatory bowel disease: Experience of a tertiary care centre in a developing country in South Asia. Singapore Med. J. 2010 51 6 484 489 20658108
    [Google Scholar]
  100. Moradkhani A. Kerwin L. Dudley-Brown S. Tabibian J.H. Disease-specific knowledge, coping, and adherence in patients with inflammatory bowel disease. Dig. Dis. Sci. 2011 56 10 2972 2977 10.1007/s10620‑011‑1714‑y 21538016
    [Google Scholar]
/content/journals/cset/10.2174/0122102981375859250512064438
Loading
A Relationship between Inflammatory Bowel Diseases and Urinary Lithiasis
Bentham Science Publishers ; https://doi.org/10.2174/0122102981375859250512064438
/content/journals/cset/10.2174/0122102981375859250512064438
/content/journals/cset/10.2174/0122102981375859250512064438
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Inflammatory bowel disease ; crohn's disease ; risk factors ; urolithiasis ; urinary stones ; ulcerative colitis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test